Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer
- 27 January 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 27 (12), 3404-3413
- https://doi.org/10.1158/1078-0432.ccr-20-3444
Abstract
PURPOSE: Actionable mutations can guide genotype-directed matched therapy. We evaluated the utility of tissue-based and plasma-based genotyping for the identification of actionable mutations and selection of matched therapy in patients with metastatic breast cancer (MBC). METHODS: Patients with MBC who underwent tissue genotyping (institutional platform, 91 gene assay) or plasma based cell-free DNA (cfDNA, Guardant360®, 73 gene assay) between January 2016 and December 2017 were included. A chart review of records to identify subtype, demographics, treatment, outcomes, and tissue genotyping or cfDNA results was performed. The incidence of actionable mutationsand the selection of matched therapy in tissue genotyping or cfDNA cohorts was determined. The impact of matched therapy status on overall survival (OS) in tissue genotyping or cfDNA subgroups was determined with Cox regression analysis. RESULTS: Of 252 patients who underwent cfDNA testing, 232 (92%) had detectable mutations, 196 (78%) had actionable mutations, and 86 (34%) received matched therapy. Of 118 patients who underwent tissue genotyping, 90 (76%) had detectable mutations, 59 (50%) had actionable mutations, and 13 (11%) received matched therapy. For cfDNA patients with actionable mutations, matched versus non-matched therapy was associated with better OS (HR 0.41, 95% CI: 0.23-0.73, p=0.002), and this remained significant in a multivariable analysis correcting for age, subtype, visceral metastases, and brain metastases (HR = 0.46, 95% CI: 0.26-0.83, p = 0.010). CONCLUSION: Plasma-based genotyping identified high rates of actionable mutations, which was associated with significant application of matched therapy and better OS in patients with MBC.Keywords
Other Versions
Funding Information
- No grant funding received for this study.
This publication has 23 references indexed in Scilit:
- Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNAPLOS ONE, 2015
- Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical TrialsJournal of Clinical Oncology, 2015
- Next-generation sequencing to guide cancer therapy.Genome Medicine, 2015
- Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast CancerClinical Cancer Research, 2015
- Anchored multiplex PCR for targeted next-generation sequencingNature Medicine, 2014
- Blood-Based Analyses of Cancer: Circulating Tumor Cells and Circulating Tumor DNACancer Discovery, 2014
- Enabling a Genetically Informed Approach to Cancer Medicine: A Retrospective Evaluation of the Impact of Comprehensive Tumor Profiling Using a Targeted Next-Generation Sequencing PanelThe Oncologist, 2014
- Liquid Biopsies: Genotyping Circulating Tumor DNAJournal of Clinical Oncology, 2014
- Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)The Lancet Oncology, 2014
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJCI Insight, 2011